Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
209.1 EUR | +0.34% | +1.31% | +15.14% |
May. 16 | ESSILORLUXOTTICA : JP Morgan maintains a Buy rating | ZD |
May. 07 | CAC40: gains altitude, banking sector in support | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.06 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.74 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.20% | 102B | B | ||
+1.18% | 19.2B | B- | ||
-16.16% | 2.35B | D+ | ||
+17.23% | 2B | C+ | ||
+26.36% | 1.21B | - | ||
-35.50% | 749M | - | ||
-7.04% | 675M | - | ||
-41.85% | 628M | B- | ||
+22.83% | 494M | - | - | |
+27.05% | 491M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EL Stock
- Ratings EssilorLuxottica